Abstract: Disclosed herein are systems and methods for providing user interface feedback regarding a cursor position on a display screen. A user may use a suitable input device for controlling a cursor in a computing environment. The displayed objects may provide feedback regarding the cursor's position. Particularly, a position of the cursor may be compared to an object's position for determining whether the cursor is positioned on the display screen at the same position as a portion of the object or within a predetermined distance of the portion of the object. In response to determining the cursor is positioned on the display screen at the same position as the portion of the object or within the predetermined distance of the portion of the object, an appearance of the portion of the object may be altered, such as, for example, brightness or color of the object portion.

Abstract: Apparatus and method are described, illustratively in an LVLS master/slave system, for detecting a circuit failure, shutting down the system as if a normal power down function has occurred, but restarting the system. Signals, including power and ground lines are monitors, mal-functions detected and the apparatus put into a power down sequence. Illustratively in the LVLS system, driving a signal line to either the power or ground rails is used as a signal to the apparatus to enter the power down sequence. The present invention, after a programmable time, then drives the signal line to the opposite rail thereby signaling the system to restart—a wake up mode. After a programmable time, the signal line is released and the system resumes normal operation.

Abstract: The present invention is directed to a dried seamless capsule comprising an alginate shell membrane encapsulating fill material, wherein: (i) said alginate shell membrane comprises a polyvalent metal ion alginate having: (a) an average M content of from 50%-62% by weight based on the weight of the M and G content, and (b) a viscosity of 35 to 80 cps when measured as a monovalent metal ion alginate in a 3.5% water solution at 20° C. using a Brookfield LV viscometer at 60 rpm and spindle #1; (ii) said alginate shell membrane encapsulates an oil present in an amount of at least 50% by weight of said fill material; (iii) said dried seamless capsule has a disintegration time of less than 12 minutes in an intestinal buffer after pretreatment for 20 minutes in a solution of 0.1 M NaCl and HCl, pH of 3, at 37° C.; and (iv) said dried seamless capsule has a dry break force strength of at least 7 kg. The present invention is also directed to methods of making and using such dried seamless capsules.

Abstract: The invention is directed to a seamless alginate capsule having a film encapsulating a fill material, in which the film comprises alginate, noncrystallizing plasticizer, and glycerol and in which a ratio by weight of noncrystallizing plasticizer to glycerol in the film is between about 1:1 and about 8:1. The invention is also directed to a method of making the seamless alginate capsules and to capsules made by the method. The capsules have excellent breaking strength and are resistant to oxidation of the fill material.

Abstract: The present invention relates to tri- or tetraspecific antibodies, their manufacture and use.

Abstract: The present invention relates to bispecific, tetravalent antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.

Abstract: An apparatus for a continuous encapsulation process is provided. The apparatus is a vibrating tubing used alone, in series, or in combination with an encapsulation apparatus, which is used alone or in series. The vibrating tubing is a flat coil, a standing spiral, or a flume. The encapsulation apparatus includes a winding having coils disposed in an aqueous gelling solution. The winding is rotatable about its longitudinal center axis. The winding has adjacently spaced coils forming a plurality of chambers. Objects to be encapsulated are added to the apparatus such that when the winding is rotated, the chambers transport a volume of objects through the length winding in the aqueous gelling solution in a predetermined time.

Abstract: The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Abstract: The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Abstract: The present invention relates to bispecific antibodies against human ErbB-2 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Abstract: The present invention relates to bispecific antibodies against human ErbB-3 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.

Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition with the above-mentioned properties.

Abstract: An apparatus for a continuous encapsulation process is provided. The apparatus is a vibrating tubing used alone, in series, or in combination with an encapsulation apparatus, which is used alone or in series. The vibrating tubing is a flat coil, a standing spiral, or a flume. The encapsulation apparatus includes a winding having coils disposed in an aqueous gelling solution. The winding is rotatable about its longitudinal center axis. The winding has adjacently spaced coils forming a plurality of chambers. Objects to be encapsulated are added to the apparatus such that when the winding is rotated, the chambers transport a volume of objects through the length winding in the aqueous gelling solution in a predetermined time.

Abstract: Degradable fibers that include biopolymers, as well as implantable devices including one or more fibers made from degradable biopolymers, e.g., alginate, chitosan, hyaluronans or their derivatives. The devices provide a combination of degradability and biocompatibility with physical properties suitable for use of the devices as implants. Exemplary devices are fastening devices including one or more biopolymer fibers. The use of such degradable biopolymers minimizes or eliminates the need for a second surgery to remove the implant, thereby eliminating the additional cost and potential complications of such a second surgery and should reduce the likelihood of secondary fractures resulting from the stress-shielding effect or the presence of screws holes that serve as stress concentrators.

Abstract: Implantable degradable devices for tissue repair or reconstruction comprising biopolymers, as well as to methods of manufacture and use thereof. The implantable device is formed by the application of pressure and the device may include up to about 65% by weight of water, based on the total weight of the implantable degradable fastening device. Methods for making implantable, degradable devices from biopolymers by application of pressure are also disclosed. The invention provides the ability to customize the device in various ways to influence properties such as mechanical strength, degradation rate and swellability.

Abstract: The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5? shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers.

Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.